Wang Yuxuan, Sundfeldt Karin, Mateoiu Constantina, Shih Ie-Ming, Kurman Robert J, Schaefer Joy, Silliman Natalie, Kinde Isaac, Springer Simeon, Foote Michael, Kristjansdottir Björg, James Nathan, Kinzler Kenneth W, Papadopoulos Nickolas, Diaz Luis A, Vogelstein Bert
Ludwig Center, Howard Hughes Medical Institute, Johns Hopkins University, Baltimore, United States.
Sidney Kimmel Comprehensive Cancer Center, Howard Hughes Medical Institute, Johns Hopkins University, Baltimore, United States.
Elife. 2016 Jul 15;5:e15175. doi: 10.7554/eLife.15175.
We determined whether the mutations found in ovarian cancers could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non-neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.
我们确定了能否在患者的卵巢囊肿液中识别出在卵巢癌中发现的突变。在23例交界性肿瘤中的19例（83%）、13例I型癌症中的10例（77%）以及18例II型癌症中的18例（100%）的囊肿液中可检测到肿瘤特异性突变。相比之下，18例患有良性肿瘤或非肿瘤性囊肿的患者的囊肿液中未发现突变。尽管需要大规模的前瞻性研究来证明这种方法的安全性和临床实用性，但我们的结果表明，囊肿液的基因评估可能有助于对大量患有这些病变的女性进行管理。
Zotero 插件
